Venous Thromboembolism During Pregnancy

Medical Complications During Pregnancy

Volumn , Issue , 2004, Pages 87-101

  McPhedran, Peter ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84903092611     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0435-0.50009-2     Document Type: Chapter

References (169)

1. Bonnar J Venous thromboembolism and pregnancy. Clin Obstet Gynaecol 1981, 8:455.
2. Kaunitz AW, Hughes JM, Grimes DA, et al. Causes of maternal mortality in the United States. Obstet Gynecol 1985, 65:605.
3. Sachs BP, Brown DAJ, Driscoll SG, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987, 316:667.
4. Bonnar J Epidemiology of venous thromboembolism in pregnancy and the puerperium. Haemostasis and Thrombosis 1992, 260. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
5. Department of Health Why Mothers Die. Report on Confidential Enquiries into Maternal Deaths in the United Kingdom 1994-1996 1998, 20-38. The Stationery Office, London.
6. Moore JG, OLeary JA, Johnson PM The changing impact of pulmonary thromboembolism in obstetrics. Am J Obstet Gynecol 1967, 97:507.
7. Bergqvist D, Bergqvist A, Lundhagen A, Matsch T Long term outcome of patients with venous thromboembolism during pregnancy. Haemostasis and Thrombosis 1992, 349. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
8. Sandison AJP, Panayiotopoulos YP, Taylor PR Venous thromboembolism during pregnancy [Letter]. N Engl J Med 1996, 335:1846.
9. de Swiet M Thromboembolism. Medical Disorders in Obstetric Practice 2002, 97-124. Blackwell Scientific, Oxford, UK. M. de Swiet (Ed.).
10. Forbes CD, Greer IA Physiology of haemostasis and the effect of pregnancy. Haemostasis and Thrombosis 1992, 15. Chapman & Hall, London, 16. I.A. Greer, A.G.G. Turpie, C.E. Forbes (Eds.).
11. LeClerc JR The diagnosis of venous thromboembolism during pregnancy and the postpartum period. Haemostasis and Thrombosis 1992, 267-303. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
12. LeClerc JR, Hirsh J Venous thromboembolic disorders. Medical Complications during Pregnancy 1988, 204-223. WB Saunders, Philadelphia. 3rd ed. G.N. Burrow, T.F. Ferris (Eds.).
13. Schmidt GA, Hall JB Pulmonary disease. Medical Disorders During Pregnancy. St 2000, 217-228. CV Mosby, Louis. W.M. Barron, M.D. Lindheimer (Eds.).
14. Virchow R Phlogose und Thrombose in Gefasssystem. Gesamelte Abhandlungen Zur Wissenschaflichen Medecin 1856, 458-636. Von Medinger Sohn, Frankfurt. R. Virchow (Ed.).
15. Drill VA, Calhoun DW Oral contraceptives and thromboembolic disease. JAMA 1968, 206:77.
16. Wessler S, Gitel S Thrombotic complications of oral contraceptives. Hemostasis and Thrombosis 1987, 1159. JB Lippincott, Philadelphia. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.).
17. Medical Complications of Pregnancy 1999, 100. WB Saunders, Philadelphia. 5th ed. G. Burrow, T.P. Duffy (Eds.).
18. Barbour LA Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997, 24:499.
19. Carter C, Gent M, LeClerc JR The epidemiology of venous thrombosis. Hemostasis and Thrombosis 1982, 1190. JB Lippincott, Philadelphia. R.W. Colman, J. Hirsh, V.J. Marder, E.W. Salzman (Eds.).
20. Witlin AG, Mattar FM, Saade GR, et al. Presentation of venous thromboembolism during pregnancy. Am J Obstet Gynecol 1999, 181:1118.
21. Lagerstedt CI, Olsson CG, Fagher BO, et al. Need for long term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 1985, 2:515.
22. Hull RD, Hirsh J, Carter C, et al. Diagnostic efficacy of impedance plethysmography for clinically suspected deep-vein thrombosis. Ann Intern Med 1985, 102:21.
23. Anderson DR, Lensing AW, Wells PS, et al. Limitations of impedance plethysmography in the diagnosis of clinically suspected deep vein thrombosis. Ann Intern Med 1993, 118:25.
24. Kearon C, Julian JA, Newman TE, Gusberg JS, et al. Noninvasive diagnosis of deep vein thrombosis. Ann Intern Med 1998, 128:663.
25. Rutherford SE, Phelan JP Deep venous thrombosis and pulmonary embolus. Critical Care Obstetrics 1991, 155-158. Blackwell, Boston, 150, 159. S.L. Clark, D.B. Cotton, G.D.V. Hankins, J.P. Phelan (Eds.).
26. Spritzer CE Magnetic resonance imaging of deep venous thrombosis in pregnant women with leg edema. Obstet Gynecol 1995, 85:603.
27. Wheeler HB, Anderson FA Impedance plethysmography and DVT diagnosis [Letter]. Ann Intern Med 1993, 119:246.
28. Tollefsen DM Disorders of hemostasis. Manual of Medical Therapeutics 1989, 337. Little, Brown, Boston. W.C. Dunagan, M.L. Ridner (Eds.).
29. Rosenow EC III, Osmundson PJ, Brown ML Pulmonary embolism. Mayo Clin Proc 1981, 56:161.
30. Wells PS, Anderson DR, Rodger M, et al. Derivation of a simple clinical model to categorize patients' probability of pulmonary embolism: Increasing the models' utility with the simpliRED D-dimer. Thromb Haemost 2000, 83:416.
31. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993, 119:104.
32. Hirsh J Anticoagulants in venous thromboembolism. Clin Haematol 1990, 3:691.
33. Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002, 87:92.
34. Edson JR, Krivit W, White JG Kaolin partial thromboplastin time: High levels of procoagulants producing short clotting times or masking deficiencies of other procoagulants or low concentrations of anticoagulant. J Lab Clin Med 1967, 70:463.
35. Poller L Laboratory control of anticoagulant therapy. Semin Thromb Hemost 1986, 12:13.
36. Greinacher A, Eckhardt T, Mussmann J, et al. Pregnancy complicated by heparin associated thrombocytopenia. Thromb Res 1993, 71:123.
37. Hall JAG, Pauli RM, Wilson KM Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980, 68:122.
38. Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986, 315:390.
39. Duffy T Hematologic aspects of pregnancy. Hematology: Basic Principles and Practice 1991, 1709. Churchill Livingstone, New York. R. Hoffman, E.J. Benz, S.J. Shattil (Eds.).
40. Ginsberg JS Fetal abnormalities and anticoagulants. Haemostasis and Thrombosis 1992, 361. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
41. Ginsberg JS, Hirsh J Use of anticoagulants during pregnancy. Chest 1989, 95(Suppl):1565.
42. Dahlman TC Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265.
43. de Swiet M, Dorrington-Ward P, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization (heparin induced osteopenia). BJOG 1983, 90:1129.
44. Griffiths HT, Liu DTY Severe heparin osteoporosis in pregnancy. Postgrad Med J 1984, 60:424.
45. Wise PH, Hall AJ Heparin induced osteopenia in pregnancy. BMJ 1980, 281:110.
46. Chan WS, Anand S, Ginsberg JG Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2000, 160:191.
47. Loscalzo J Fibrinolytic therapy. Williams Hematology 2001, 1803-1811. McGraw-Hill, New York. 6th ed. E. Beutler, M.A. Lichtman, B.S. Coller (Eds.).
48. Turrentine MA, Braems G, Ramirez MA Use of thrombolytics for the treatment of thromboembolic disease during pregnancy. Obstet Gynecol Surv 1995, 50:534.
49. Grand A, Ghadban W, Perret SP, et al. Ilio-femoral thrombosis treated with tissue plasminogen activator in a pregnant woman. Ann Cardiol Angeiol (Paris) 1996, 45:517.
50. Morrison AE, Walker IO, Black WP Protein C deficiency presenting as deep venous thrombosis in pregnancy. Case report. BJOG 1988, 95:1077.
51. Seligsohn U, Lubetsy A Medical progress: Genetic susceptibility to venous thrombosis. N Engl J Med 2001, 344:1222.
52. Vogel J, de Moerloose PA, Bounameaux H Protein C deficiency and pregnancy: A case report. Obstet Gynecol 1989, 73:455.
53. Winter JH, Fenech H, Ridler W, et al. Familial antithrombin III deficiency. Q J Med 1982, 204:373.
54. Gallus AS Anticoagulants in the prevention and treatment of thromboembolic problems in pregnancy including cardiac problems. Haemostasis and Thrombosis 1992, 334-335. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
55. Stamm H Die thromboembolischen Erkrankungen. Fortschr Geb Gynakol 1969, 39:8.
56. Friedrich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor deficient women. Ann Intern Med 1996, 125:955.
57. Trauscht-Van Horn JJ, Capeless EL, Easterling TR, Bovill EG Pregnancy loss and thrombosis with protein C deficiency. Am J Obstet Gynecol 1992, 167:968.
58. McColl MD, Walker ID, Freer IA The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. BJOG 1999, 106:756.
59. Gerhardt A, Scharf RE, Zotz RB Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 2003, 90:77.
60. Toglia MR, Weg JG Venous thromboembolism during pregnancy. N Engl J Med 1996, 335:108.
61. 506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol 1996, 92:473.
62. Thaler E, Lechner K Antithrombin III deficiency and thromboembolism. Clin Haematol 1981, 10:369.
63. De Stefano V, Leone G, DeCarolis S, et al. Management of pregnancy in women with antithrombin III congenital defect: Report of four cases. Thromb Haemost 1988, 59:193.
64. Dizon-Townson D, Nelson LM, Jang H, et al. The incidence of factor V Leiden mutation in an obstetric population and its relationship to deep vein thrombosis. Am J Obstet Gynecol 1997, 176:883.
65. Hallak M, Sanderowicz J, Cassel A, et al. Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol 1997, 176:889.
66. Pabinger I, Schneider B Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) Study Group on Natural Inhibitors. Arterioscler Thromb Vasc Biol 1996, 16:742.
67. Miletich J, Sherman L, Broze G Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987, 317:991.
68. Haverkate F, Samama M Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 1995, 73:151.
69. Nilsson IM, Ljungner H, Tengborn L Two different mechanisms in patients with venous thrombosis and defective fibrinolysis. BMJ 1985, 18:1453.
70. Ballegeer V, Mombarts P, Declerk PJ, et al. Fibrinolytic response to venous occlusion and fibrin fragment D-dimer levels in normal and complicated pregnancy. Thromb Haemost 1987, 58:1030.
71. Bonnar J, McNicol GP, Douglas AS Fibrinolytic enzyme system and pregnancy. BMJ 1969, 3:387.
72. Woodfield DG, Cole SK, Allan AGE, et al. Serum fibrin degradation products throughout normal pregnancy. BMJ 1968, 4:665.
73. Many A, Pauzner R, Carp M Treatment of patients with antiphospholipid antibodies during pregnancy. Am J Reprod Immunol 1992, 28:216.
74. Lubbe WF, Butler WS Acquired defects of coagulation-the lupus anticoagulant. Haemostasis and Thrombosis 1992, 392. Chapman & Hall, London. I.A. Greer, A.G.G. Turpie, C.D. Forbes (Eds.).
75. Hunt BJ, Khamashta MA Management of the Hughes syndrome. Clin Exp Rheumatol 1996, 14:115.
76. Malm J, Laurell M, Dahlback B, et al. Changes in the plasma levels of vitamin K dependent protein C and S and of C4b-binding protein during pregnancy and oral contraception. Br J Haematol 1988, 68:437.
77. Gastineau DA, Kazimer KJ, Nichols WL, et al. Lupus anticoagulant: An analysis of clinical and laboratory features of 219 cases. Am J Hematol 1985, 19:265.
78. Triplett DA, Brandt JT, Musgrave KA, Orr CA The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988, 259:550.
79. Mannucci PM, Canciani MT, Mari D, et al. The varied sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus like anticoagulant. Scand J Haematol 1979, 22:423.
80. Infante-Rivard C, David H, Gauthier R, Rivard GE Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A case control study. N Engl J Med 1991, 325:1063.
81. Finazzi G, Brancaccio V, Moia M, et al. Natural history and risk factor for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530.
82. Lubbe WF, Walker EB Chorea gravidarum associated with circulating lupus anticoagulant: Successful outcome of pregnancy with prednisone and aspirin therapy. BJOG 1983, 90:487.
83. Reece AE, Gabrielli, Cullen MF, et al. Recurrent adverse pregnancy outcome and antiphospholipid antibodies. Am J Obstet Gynecol 1990, 163:162.
84. Lima F, Khamashta MA, Buchanan NMM, et al. A study of 60 pregnancies with the antiphospholipid syndrome. Clin Exp Rheumatol 1996, 14:131.
85. Brenner B, Mandel H, Lanir N, et al. Activated protein C resistance can be associated with recurrent fetal loss. Br J Haematol 1997, 97:551.
86. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999, 341:384.
87. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. Lancet 1996, 348:1734.
88. Rai R, Regan L, Hadley E, et al. Second trimester pregnancy loss is associated with activated protein C resistance. Br J Haematol 1996, 92:489.
89. Therakan T, Baxi LV, Diuguid D Protein S deficiency in pregnancy: A case report. Am J Obstet Gynecol 1993, 168:141.
90. Brenner B Thrombophilia and pregnancy. Clin Adv Hematol Oncol 2003, 1:351.
91. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine ?-synthase deficiency. Am J Hum Genet 1985, 37:1.
92. Walters B, de Swiet M Bone disease, disease of the parathyroid glands, and some other metabolic disorders. Medical Disorders in Obstetric Practice 1989, 713. Blackwell Scientific, Oxford, UK. M. de Swiet (Ed.).
93. Constantine G, Green A Untreated homocystinuria: A maternal death in a woman with four pregnancies. BJOG 1987, 94:803.
94. Lamon JM, Lenke RR, Levy HL, et al. Selected metabolic diseases. Genetic Diseases in Pregnancy 1981, 6-8. Academic Press, New York. J.D. Schulman, J.L. Simpson (Eds.).
95. Den Heijer M, Koster T, Blom HJ, et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996, 334:759.
96. Peng F, Triplett D, Barna L, Morrical D Pulmonary embolism and premature labor in a patient with both factor V Leiden mutation and methylenetetrahydrofolate reductase gene C677T mutation. Thromb Res 1996, 83:243.
97. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994, 14:465.
98. McElin TW, LaPata RE, Westenfelder GO, et al. Postpartum ovarian vein thrombosis and microaerophilic streptococcal sepsis. Obstet Gynecol 1970, 35:632.
99. Witlin A, Sibai BM Postpartum ovarian vein thrombosis after vaginal delivery: A report of 11 cases. Obstet Gynecol 1995, 85:7757.
100. Malkamy H Heparin therapy in postcesarean septic pelvic thrombophlebitis. Int J Gynaecol Obstet 1980, 17:564.
101. Salomon O, Apter S, Shahan D, et al. Risk factors associated with postpartum ovarian vein thrombosis. Thromb Haemost 1999, 82:1015.
102. Sanson B-J, Lensing AWA, Prins MH, et al. Safety of low molecular weight heparin in pregnancy: A systematic review. Thromb Haemost 1999, 81:668.
103. Bahnson RR, Wendel EF, Vogelzang RL Renal vein thrombosis following puerperal ovarian vein thrombophlebitis. Am J Obstet Gynecol 1985, 152:290.
104. Weiner CP Diagnosis and management of thromboembolic disease during pregnancy. Clin Obstet Gynecol 1985, 28:107.
105. Brown CE, Stettler RW, Twickler D, et al. Puerperal septic pelvic thrombophlebitis: Incidence and response to heparin therapy. Am J Obstet Gynecol 1999, 181:143.
106. Salomon D, Apter S, Shaham D, et al. Risk factors associated with postpartum ovarian vein thrombosis. Thromb Haemost 1999, 82:1015.
107. Lanska DJ, Kryscio RJ Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000, 31:1274.
108. Bousser MG, Chiras J, Bories J, et al. Cerebral venous thrombosis-a review of 38 cases. Stroke 1985, 16:199.
109. Halpern JP, Morris JGL, Driscoll GL Anticoagulants and cerebral venous thrombosis. Aust N Z J Med 1984, 14:643.
110. Wiebers DO, Whisnant JP The incidence of stroke among pregnant women in Rochester Minnesota 1955 through 1979. JAMA 1985, 254:3055.
111. Arunkalaivanan AS, Barrington JW Late puerperal sagittal sinus thrombosis associated with primary antiphospholipid antibody syndrome. J Obstet Gynecol 2002, 22:682.
112. Burneo JG, Elias SB, Barkley GL Cerebral venous thrombosis due to protein S deficiency in pregnancy. Lancet 2002, 359:892.
113. Galan HL, McDowell AB, Johnson PR, et al. Puerperal cerebral venous thrombosis associated with decreased free protein S. J Reprod Med 1995, 40:859.
114. Gokcil Z, Odabasi Z, Vural O, et al. Cerebral venous thrombosis in pregnancy: The role of protein S deficiency. Acta Neurol Belg 1998, 98:36.
115. Martinelli I, Landi G, Merati G, et al. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996, 75:373.
116. Wechsler B, Genereau T, Biousse V, et al. Pregnancy complicated by cerebral venous thrombosis in Behçet's disease. Am J Obstet Gynecol 1995, 173:1627.
117. Curvers J, Nap AW, Thomasson MC, et al. Effect of in-vitro fertilization treatment and subsequent pregnancy on the protein C pathway. Br J Haematol 2001, 115:400.
118. Aurousseau MH, Samama MU, Belhassen A, et al. Risk of thromboembolism in relation to an in-vitro fertilization programme: Three case reports. Hum Reprod 1995, 10:94.
119. Hignett M, Spence JE, Claman P Internal jugular vein thrombosis: A late complication of ovarian hyperstimulation syndrome despite mini-dose heparin prophylaxis. Hum Reprod 1995, 10:3121.
120. Ellis MH, Nun IB, Rathaus V, et al. Internal jugular vein thrombosis in patients with ovarian hyperstimulation syndrome. Fertil Steril 1998, 69:140.
121. Kligman I, Noyes N, Benadiva CA, Rosenwaks Z Massive deep vein thrombosis in a patient with antithrombin III deficiency in a patient undergoing ovarian stimulation for in vitro fertilization. Fertil Steril 1995, 63:673.
122. Hellgren M, Blomback M Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I: Normal condition. Gynecol Obstet Invest 1981, 12:141.
123. Stirling Y, Woolf I, North WRS, et al. Haemostasis in normal pregnancy. Thromb Haemost 1984, 52:176.
124. Beller FK, Ebert C The coagulation and fibrinolytic enzyme system in normal pregnancy and the puerperium. Eur J Obstet Gynaecol Reprod Biol 1982, 13:177.
125. Inglis TCM, Stuart J, George AJ, et al. Haemostatic and rheological changes in normal pregnancy and pre-eclampsia. Br J Haematol 1982, 50:461.
126. Scholtes MCW, Gerretsen G, Haak HL The factor VIII ratio in normal and pathological pregnancies. Eur J Obstet Gynaecol Reprod Biol 1983, 16:89.
127. Bellart J, Gilabert R, Fontcuberta J, et al. Fibrinolysis changes in normal pregnancy. J Prenat Med 1997, 25:368.
128. Lecander I, Astedt B Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986, 62:221.
129. Nilsson IM, Felding P, Lecander I, et al. Different types of plasminogen activator inhibitors in plasma and platelets in pregnant women. Br J Haematol 1986, 62:215.
130. Booth N, Reith A, Bennalt B, et al. A plasminogen activator inhibitor (PAI-2) circulates in two molecular forms in pregnancy. Thromb Haemost 1988, 59:77.
131. Thorburn J, Drummond MM, Whigham KA, et al. Blood viscosity and haemostatic factors in late pregnancy, pre-eclampsia, and fetal growth retardation. BJOG 1982, 89:117.
132. Bellart J, Gilabert R, Miralles RM, et al. Endothelial cell markers and fibrinopeptide A to D-dimer ratio as a measure of coagulation and fibrinolysis balance in normal pregnancy. Gynecol Obstet Invest 1998, 46:17.
133. Chabloz O, Reber G, Boehlen F, et al. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br J Haematol 2001, 115:150.
134. Francalanci L, Comeglio P, Alessandro-Liotta A, et al. D-dimer plasma levels during normal pregnancy measured by specific ELISA. Int J Clin Lab Res 1997, 27:65.
135. Choi JW, Pai SH Tissue plasminogen activator levels change with plasma fibrinogen concentrations during pregnancy. Ann Hematol 2002, 81:611.
136. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998, 79:1166.
137. Kjellberg U, Andersson NE, Rosen S, et al. APC resistance and other hemostatic variables during pregnancy and the puerperium. Thromb Haemost 1999, 81:527.
138. Alving BM, Comp PC Recent advances in understanding clotting and evaluating patients with recurrent thrombosis. Am J Obstet Gynecol 1992, 167:1184.
139. Comp PC, Thurman GR, Welsh J, et al. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986, 68:881.
140. Lefkowitz JB, Clark SH, Barbour LA Comparison of protein S functional and antigenic assays in normal pregnancy. Am J Obstet Gynecol 1996, 175:657.
141. Oruc S, Saruc M, Koyuncu, et al. Changes in the plasma activities of protein C and S during pregnancy. Aust N Z J Obstet Gynaecol 2000, 40:448.
142. Boehlen F, Hohlfeld P, Extermann P, et al. Platelet count at term in pregnancy: A reappraisal of the threshold. Obstet Gynecol 2000, 95:29.
143. Cerneca F, Ricci G, Simeone R, et al. Coagulation and fibrinolysis changes in pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a reactive fibrinolysis. Eur J Obstet Gynaecol Reprod Biol 1997, 73:31.
144. Shimano S, Kurosu T, Hayama K, et al. Differences of IgG and IgM antibodies to phospholipids and APTT among non-pregnant and pregnant women. J Obstet Gynecol Res 1998, 24:299.
145. Hayashi M, Inoue T, Hoshimoto K, et al. The levels of five markers of hemostasis and endothelial status at different stages of normotensive pregnancy. Acta Obstet Gynecol Scand 2002, 81:208.
146. Mannucci PM, Vigano S, Bottasso B, et al. Protein C antigen during pregnancy, delivery, and the puerperium. Thromb Haemostas 1984, 52:217.
147. Persson BL, Steinberg P, Holmberg L, et al. Transaminating enzymes in maternal plasma and placenta in human pregnancies complicated by intrauterine growth retardation. J Dev Physiol 1980, 2:37.
148. Weiner CP, Brandt J Plasma antithrombin III activity in normal pregnancy. Obstet Gynecol 1980, 56:601.
149. Kearon C, Crowther M, Hirsh J Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000, 51:169.
150. Rosene-Montella K, Barbour LA Thromboembolic disease and hypercoagulable states. Medical Care of the Pregnant Patient 2000, 423-448. American College of Physicians, Philadelphia. R.V. Lee, K. Rosene-Montella, L.A. Barbour (Eds.).
151. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol 1999, 94:730.
152. Simpson EL, Lawrenson RA, Nightingale AL, Farmer RD Venous thromboembolism in pregnancy and the puerperium: Incidence and additional risk factors from a London perinatal database. BJOG 2001, 108:56.
153. Soomro RM, Bucur IJ, Noorani S Cumulative incidence of venous thromboembolism during pregnancy and puerperium: A hospital based study. Angiology 2002, 53:429.
154. Bergqvist A, Bergqvist D, Hallbrook T Acute deep venous thrombosis after caesarian section. Acta Obstet Gynecol Scand 1979, 58:473.
155. Bergqvist A, Bergqvist D, Hallbrook T Deep venous thrombosis during pregnancy. Acta Obstet Gynecol Scand 1983, 62:443.
156. Kierkegaard A Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynecol Scand 1983, 62:239.
157. Andersen BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thrombosis during pregnancy and puerperium-an 11-year Danish population based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998, 77:170.
158. Tan JY Thrombophilia in pregnancy. Ann Acad Med Singapore 2002, 31:328.
159. Gillis S, Shushan A, Eldor A Use of low molecular weight heparin for prophylaxis and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 1992, 39:297.
160. Melissari E, Parker CJ, Wilson HV, et al. Use of low molecular weight heparin in pregnancy. Thromb Hemost 1992, 68:652.
161. Rasmussen C, Wadt J, Jacobsen B Thromboembolic prophylaxis with low molecular weight heparin during pregnancy. Int J Gynaecol Obstet 1994, 47:121.
162. Sturridge F, de Swiet M, Letsky E The use of low molecular weight heparin for thromboprophylaxis in pregnancy. BJOG 1994, 101:69.
163. Boda Z, Laszlo P, Rejto L, et al. LMWH vs thromboprophylaxis during the whole period of pregnancy [Letter]. Thromb Haemost 1996, 76:124.
164. Lee LH, Liauw PCY, Ng ASH Low molecular weight heparin for thromboprophylaxis during pregnancy in two patients with mechanical mitral valve replacement. Thromb Haemost 1996, 76:628.
165. Daskalaskis G, Antsaklis A, Papageorgion I, Michalas S Thrombosis prophylaxis after treatment during pregnancy. Eur J Obstet Gynaecol 1997, 74:165.
166. Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997, 77:39.
167. Thomson AJ, Walker ID, Greer IA Low molecular weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998, 352:1904.
168. Ensom MH, Stephenson MD Low molecular weight heparins in pregnancy. Pharmacotherapy 1999, 19:1013.
169. Ellison J, Walker ID, Green IA Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Int J Gynaecol Obstet 2000, 107:1116.